Ifct-1701
WebThe DICIPLE phase three trial, also entitled IFCT-1701, has had the goal to look whether a shorter duration of immunotherapy by Nivo plus Ipilimumab would be as efficient as a longer one, two years, in non-small cell lung cancer, in first-line setting. Web14 okt. 2024 · Shorter Duration of Treatment With Nivolumab Plus Ipilimumab in Advanced NSCLC. By: Justine Landin, PhD Posted: Friday, October 14, 2024. Nivolumab plus …
Ifct-1701
Did you know?
Web24 feb. 2024 · This is a phase II-III randomized, open-labelled, multicentre study for NSCLC patients who are naive of treatment for advanced disease. Patients will be given first-line chemotherapy + pembrolizumab: platinum doublet for at least 3 cycles, either paclitaxel-carboplatin for patient with SCC or 3 cycles of pemetrexed-platinum salt followed by 2 … Web7 sep. 2024 · 972O Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of …
Web11 sep. 2024 · Only an academic trial would compare short vs extended immunotherapy treatment. 6-months Nivolumab + ipilimumab versus continuation in patients with NSCLC … Web2176 - IFCT-1701 DICIPLE: a randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet immunotherapy until progression versus observation in patients with …
Web30 mei 2024 · 9003 Background: Benefit coming from maintenance treatment appears greater for switch maintenance in pts with disease stabilization (SD) while it might be … Webresponse? Several trials, including IFCT-1701 DICIPLE (NCT03469960), are currently underway to offer answers to these questions. Now that a combination of chemotherapy and immunotherapy is becoming the standard first-line treatment for all histologies and for all PD-L1 statuses, it is reasonable to expect greatly improved outcomes
Web9 nov. 2024 · Oft zeigt die Erfahrung im klinischen Alltag bereits Trends auf, die noch nicht mit Studiendaten untermauert werden können. Auf dem ESMO-Kongress 2024 wurden nun einige Studien vorgestellt, die die Praxiserfahrung von Onkolog*innen in der Therapie des nichtkleinzelligen Lungenkarzinoms (NSCLC) auch auf eine wissenschaftlich-empirische …
WebDICIPLE (IFCT-1701) Appareil pulmonaire. Essai clinique fermé. Public cible. Adulte. A randomized phase 3 trial comparing continuation Nivolumab-Ipilimumab doublet … temas para whatsapp gb baixarWeb12 sep. 2024 · Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation n patients with advanced non-small cell lung cancer (aNSCLC): Results of … temas para win 11WebRequest PDF On Jan 1, 2024, A.-C. Toffart and others published Étude de phase II-III randomisée (IFCT-1701 DICIPLE), comparant une continuation du doublet … temas para win 10Web8 sep. 2024 · Sarah B. Goldberg MD, MPH. Recommend. Sunday, September 11, 2024. 8:30–10:00 CEST; Proffered Paper Session. Non-Metastatic NSCLC and Other Thoracic Malignancies. LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC): updated results … temas para win7 32 bitsWebSondages & annonces des membres IFCT; Formations & évènements; Espace patients. Les essais cliniques de l'IFCT en vidéos; Les projets de recherche de l'IFCT sur données et … temas para win 7 64 bitsWebMartin Reck, MD, PhD, of Germany’s Lung Clinic Grosshansdorf, details two trials that included patients with advanced non–small cell lung cancer: 3-year survival outcomes in the EMPOWER-Lung 1 study of continued cemiplimab-rwlc beyond disease progression with the addition of chemotherapy, and phase III results from the IFCT-1701 trial of nivolumab … temas para windows 10 duas telasWeb1 st -line immunotherapy (io) is a standard treatment for patients (pts) with aNSCLC and no targetable mutation. Classical 2-years io duration does not rely on solid evidence. We … temas para win 8.1